BACKGROUND: Postoperative chemotherapy (CMT) or chemoradiotherapy (CRT) is commonly recommended for gastric cancer (GC) patients in order to improve survival. However, some factors that prevent patients from return to intended oncologic treatment (RIOT) may increase the risk of recurrence and decrease the survival benefits achieved with curative resection. The aim of this study was to determine the frequency and factors associated with inability to RIOT and their impact on survival. METHODS: This retrospective study included stage II/III GC patients treated with potentially curative gastrectomy. Patients who could return to intended oncologic treatment (RIOT group) and those who could not (inability to RIOT group) were analyzed. RESULTS: Of the 313 eligible GC patients, 89 (28.4%) and 85 (27.2%) patients receive CRT and CMT, respectively, representing a RIOT rate of 55.6%. The main reason was attributed to general poor performance status (30.2%), followed by surgical postoperative complications (POC) (20.1%). Older age, higher ASA, D1 lymphadenectomy, and major POC were related to inability to RIOT. Older age, neutrophil-lymphocyte ratio (NLR), and major POC were independent risk factors for inability to RIOT. Five-year DFS and OS were worse for the inability to RIOT group than for the RIOT group (p = 0.008 and p = 0.004, respectively). In multivariate analyses, absence of neoadjuvant therapy, total gastrectomy, pT3/T4, pN+, and inability to RIOT were associated with worse DFS. Type of gastrectomy, lymphadenectomy, pN status, Rx resection, and RIOT group were associated with OS. CONCLUSION: Older age, high NLR, and major POC were risk factors for inability to RIOT. RIOT was an independent predictor of survival.
BACKGROUND: Postoperative chemotherapy (CMT) or chemoradiotherapy (CRT) is commonly recommended for gastric cancer (GC) patients in order to improve survival. However, some factors that prevent patients from return to intended oncologic treatment (RIOT) may increase the risk of recurrence and decrease the survival benefits achieved with curative resection. The aim of this study was to determine the frequency and factors associated with inability to RIOT and their impact on survival. METHODS: This retrospective study included stage II/III GCpatients treated with potentially curative gastrectomy. Patients who could return to intended oncologic treatment (RIOT group) and those who could not (inability to RIOT group) were analyzed. RESULTS: Of the 313 eligible GCpatients, 89 (28.4%) and 85 (27.2%) patients receive CRT and CMT, respectively, representing a RIOT rate of 55.6%. The main reason was attributed to general poor performance status (30.2%), followed by surgical postoperative complications (POC) (20.1%). Older age, higher ASA, D1 lymphadenectomy, and major POC were related to inability to RIOT. Older age, neutrophil-lymphocyte ratio (NLR), and major POC were independent risk factors for inability to RIOT. Five-year DFS and OS were worse for the inability to RIOT group than for the RIOT group (p = 0.008 and p = 0.004, respectively). In multivariate analyses, absence of neoadjuvant therapy, total gastrectomy, pT3/T4, pN+, and inability to RIOT were associated with worse DFS. Type of gastrectomy, lymphadenectomy, pN status, Rx resection, and RIOT group were associated with OS. CONCLUSION: Older age, high NLR, and major POC were risk factors for inability to RIOT. RIOT was an independent predictor of survival.
Authors: Daniel José Szor; Andre Roncon Dias; Marina A Pereira; Marcus F K P Ramos; Bruno Zilberstein; Ivan Cecconello; Ulysses Ribeiro Journal: J Surg Oncol Date: 2018-03-06 Impact factor: 3.454
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Linda X Jin; Dominic E Sanford; Malcolm Hart Squires; Lindsey E Moses; Yan Yan; George A Poultsides; Konstantinos I Votanopoulos; Sharon M Weber; Mark Bloomston; Timothy M Pawlik; William G Hawkins; David C Linehan; Carl Schmidt; David J Worhunsky; Alexandra W Acher; Kenneth Cardona; Clifford S Cho; David A Kooby; Edward A Levine; Emily Winslow; Neil Saunders; Gaya Spolverato; Graham A Colditz; Shishir K Maithel; Ryan C Fields Journal: Ann Surg Oncol Date: 2016-03-22 Impact factor: 5.344
Authors: Georgios Karagkounis; Malcolm Hart Squires; Marcovalerio Melis; George A Poultsides; David Worhunsky; Linda X Jin; Ryan C Fields; Gaya Spolverato; Timothy M Pawlik; Konstantinos I Votanopoulos; Edward A Levine; Carl Schmidt; Mark Bloomston; Clifford S Cho; Sharon Weber; Antonio Masi; Russell Berman; H Leon Pachter; Charles A Staley; Elliot Newman; Shishir K Maithel; Ioannis Hatzaras Journal: J Gastrointest Surg Date: 2017-09-29 Impact factor: 3.452
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Andre Roncon Dias; Anna Carolina Batista Dantas; Daniel Jose Szor; Ulysses Ribeiro; Bruno Zilberstein; Ivan Cecconello Journal: World J Gastrointest Surg Date: 2021-04-27